Emraclidine is under clinical development by Cerevel Therapeutics and currently in Phase I for Psychosis. According to GlobalData, Phase I drugs for Psychosis have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Emraclidine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Emraclidine (CVL-231) is under development for the treatment of schizophrenia experiencing an acute exacerbation of psychosis and Alzheimer’s disease psychosis (psychosis). The drug candidate acts by targeting muscarinic acetylcholine receptor M4. The drug candidate is a positive allosteric modulator, or PAM. It is administered through oral route. It was also under development for the treatment of Alzheimer’s disease.
Cerevel Therapeutics overview
Cerevel Therapeutics is a biopharmaceutical company. It develops and commercializes medicines for the treatment of central nervous system (CNS) disorders. Cerevel Therapeutics is headquartered in Boston, Massachusetts, United States.
For a complete picture of Emraclidine’s drug-specific PTSR and LoA scores, buy the report here.